NEWSROOM Press Releases

    254 Results

    chief executive office of biodesix, scott hutton

    Biodesix CEO Scott Hutton Named to The Healthcare Technology Report’s List of Top 25 Biotech CEOs in 2022

    Biodesix CEO named in The Healthcare Technology Report’s list of Top 25 Biotech CEOs of 2022, recognizing the most accomplished executives in biotech.

    Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® Test

    announced positive coverage decisions from four private payers including Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Health Plan (CDPHP) of New York

    Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors

    Biodesix announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company’s Board of Directors effective January 3, 2023.

    Biodesix Announces Publication Further Validating the use of Liquid Biopsies and NGS Techniques to Provide Clinical Information for Patients with Cancer

    Biodesix today announced that new data were published in the peer-reviewed journal, Diagnostics (Basel), in an article titled, “Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants.”

    Biodesix to Report Third Quarter 2022 Financial Results on Nov. 3, 2022

    Biodesix will release financial results for the third quarter before the open of trading on November 3. Biodesix’s will host a conference call and webcast to discuss its financial results and provide a general business update at 8:00 a.m. ET.

    Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022

    Biodesix announced today that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4

    Biodesix to Present Data at the CHEST 2022 Annual Meeting

    Biodesix to Present Data at the CHEST 2022 Annual Meeting Demonstrating High Sensitivity of the Nodify XL2® Blood-Based Lung Nodule Test in Various Patient Populations, Including Individuals Participating in Lung Cancer Screening Programs

    Biodesix to Present Data at IASLC 2022 World Conference

    Biodesix to Present Data at IASLC 2022 World Conference Demonstrating that the VeriStrat® Test is Predictive of Progression Free Survival and Overall Survival in Patients with Low or Negative PD-L1 Treated with Immune Checkpoint Inhibitors

    Biodesix to Present at the Canaccord Genuity 42nd Annual Growth Conference

    Scott Hutton, Chief Executive Officer of Biodesix, will present at the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022.

    Biodesix Announces First Quarter 2022 Results and Highlights

    First Quarter 2022 Financial Results

    Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine

    Biodesix named the leading Proteomics Solutions Company in the U.S. by Life Sciences Review Magazine issue, Top 10 Proteomics Solutions Companies of 2022.

    https://cts.businesswire.com/ct/CT?id=bwnews&sty=20220118005460r1&sid=acqr8&distro=nx&lang=en

    Biodesix Announces the Launch of its GeneStrat NGS™ Test and the IQLung™ Testing Strategy with Unprecedented Time to Results

    Genomic and proteomic diagnostics for lung cancer help physicians better identify patients eligible for targeted therapy or clinical trial enrollment.

    Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common Stock

    Biodesix announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions.

    Biodesix Announces Proposed Public Offering of Common Stock

    Biodesix announced that it has commenced an underwritten public offering of $30 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses.

    Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 Million

    Biodesix announced that it has obtained a term loan facility for up to $50 million from Perceptive Advisors, a leading healthcare investment firm focused on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare.

    Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

    Data confirms the ability of the VeriStrat® test to predict outcomes in patients with Non-small Cell Lung Cancer treated with immunotherapy regimens.

    Biodesix Announces Third Quarter 2022 Results and Highlights

    Third quarter 2022 core Lung Diagnostic revenue of $9.2 million increased 102% over the comparable period in 2021; U.S. Federal Supply Schedule Contract expands coverage to Veterans Health Administration and Military Health System Medical Centers for its entire Lung Diagnostic portfolio.

    Biodesix Awarded U.S. Federal Supply Schedule Contract for Its Comprehensive Lung Cancer Diagnostic Testing Solutions

    Biodesix Expands Coverage to Veterans Health Administration and Military Health System Medical Centers for Its Entire Lung Diagnostic Portfolio

    Biodesix Announces Preliminary Revenue for Third Quarter 2022

    Biodesix expects to report third quarter 2022 total revenue to be in the range of $10.6 million to $11.2 million, representing growth of 62% to 71% over the third quarter 202, reflecting continued growth in the Company’s core lung diagnostic testing.

    Biodesix to Participate in Two Upcoming Investor Conferences in September

    Biodesix to participate at Morgan Stanley 20th Annual Global Healthcare Conference and H.C. Wainwright 24th Annual Global Investment Conference

    Biodesix Announces Second Quarter 2022 Results and Highlights

    Biodesix, Inc. (Nasdaq: BDSX) announced its financial and operating results for second quarter ended June 30, 2022 and provided a corporate update.

    Canaccord Genuity 42nd Annual Growth Conference

    Rewatch the live fireside chat during Canaccord Genuity 42nd Annual Growth Conference, featuring Scott Hutton, CEO of Biodesix Inc.

    Biodesix Named a Top 100 Healthcare Technology Company of 2022

    Biodesix is recognized in the Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022.

    https://cts.businesswire.com/ct/CT?id=bwnews&sty=20220314005150r1&sid=acqr8&distro=nx&lang=en

    Biodesix Announces Fourth Quarter and Year End 2021 Results and Highlights

    Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods

    Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis

    Adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment

    Biodesix Obtains Medicare Coverage for Nodify CDT® Lung Nodule Test

    The Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, provides coverage for the Nodify CDT® lung nodule test.

    Biodesix Announces Research Agreement with Top US Cancer Center

    Aim is to develop and commercialize new pipeline oncology biomarker assay in collaboration with Memorial Sloan Kettering Cancer Center and Bio-Rad, Inc.

    Biodesix to Present at the 42nd Annual William Blair Growth Stock Conference

    Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9 in Chicago

    Biodesix Announces impactful Clinical Data on the Primary Immune Response (PIR) test at the IASLC 2022 Therapies of Lung Cancer Meeting

    Biodesix announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting.